Long-term safety of two psoriasis drugs in people with heart risk
Treatments studied
Part of Skin clinical trials.
This study compares two medications for psoriasis (deucravacitinib and ustekinumab) over a long period. It's designed for people with moderate-to-severe psoriasis who also have certain risk factors for heart disease, like high blood pressure or diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have moderate-to-severe plaque psoriasis
- Your doctor thinks you are a candidate for light therapy or stronger medications (like ustekinumab)
- You have at least one risk factor for heart disease (like smoking, high blood pressure, diabetes, or a history of heart attack or stroke)
- You have not had a heart attack, stroke, or blood clot in the last 90 days
- You have not had a recent unstable heart problem that required hospitalization
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests an investigational oral medication called deucravacitinib for teenagers (adolescents) with moderate to severe plaque psoriasis. It aims to see if the drug is safe and works well.
This study checks whether deucravacitinib works well and is safe in children and teens with moderate to severe plaque psoriasis. It also looks at drug levels in the body to help understand how the treatment behaves over time.
This study compares two oral medications, deucravacitinib and apremilast, for adults with plaque psoriasis in Japan. It looks at how well each drug works in real-world use.
This trial tests whether a combination of two drugs (vunakizumab and recaticimab) can help people who have both moderate-to-severe plaque psoriasis and high cholesterol. It aims to see if the treatment is safe and effective for both conditions.
This Phase 4 study looks at how well a psoriasis medicine called secukinumab works, and what happens when treatment is stopped in people with moderate-to-severe plaque psoriasis. It may help show the best way to manage symptoms and prevent flare-ups.
This trial tests a new oral medication, CS32582, for people with moderate to severe plaque psoriasis. It aims to see if the drug is safe and effective at reducing skin symptoms like redness, thickness, and scaling.
Hear when a new Plaque Psoriasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.